Neos Therapeutics (NEOS) Posts Wider-than-Expected Q3 Loss

Neos Therapeutics (NASDAQ: NEOS) reported Q3 EPS of ($0.77), $0.19 worse than the analyst estimate of ($0.58). Revenue for the quarter came in at $221 thousand versus the consensus estimate of $800 thousand.

For earnings history and earnings-related data on Neos Therapeutics (NEOS) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Azitra, Inc. (AZTR) Tops Q2 EPS by 54c
• Activist investors push Seer, Inc. to disclose go-private timeline